Abstract
Proteins of the pregnancy specific β-1 glycoprotein (PSG) family are renowned for their elevated expression during pregnancy. Only few reports have investigated their expression in adenocarcinomas. We studied the expression of PSG1 in pancreatic adenocarcinoma (PDAC). In a cohort of 104 patient samples, immunohistochemical analysis determined PSG1 expression in every specimen. PSG1 was found at apical and cytoplasmic localization or solely at cytoplasmic localization, with the latter case being correlated to shortened median survival (25 vs 11 months, logrank p-value < 0.001). At the same time, enzyme linked immunosorbent assay (ELISA) did not detect elevated PSG1 levels in the plasma of PDAC patients as opposed to the plasma of healthy, non-pregnant control individuals. We also probed the impact of PSG1 expression in a murine tumor model system, using subcutaneous injection of Colo-26 cells into immunocompetent BALB/c mice. Here, tumor growth was not affected by the expression of human PSG1. Our study reaffirms interest into the tumor-contextual biology of PSG proteins.
| Original language | English |
|---|---|
| Journal | Journal of Cancer |
| Volume | 7 |
| Issue number | 14 |
| Pages (from-to) | 2018-2027 |
| Number of pages | 10 |
| ISSN | 0007-0920 |
| DOIs | |
| Publication status | Published - 01.01.2016 |
Funding
We thank the SFB50 Z1 project members Prof. Dr. Silke Lassmann and Nicola Bittermann for initial establishment of stainings. This study was funded by the Deutsche Forschungsgemeinschaft (SCHI 871/2 and SCHI 871/5, SCHI 871/6, GR 1748/6, INST 39/900-1 and SFB850-Project B8 to O. S., WE 5085/1-1 to U. W.), the European Research Council (ERC-2011-StG 282111-ProteaSys to O.S.), and the Excellence Initiative of the German Federal and State Governments (EXC 294, BIOSS to O.S.). The article processing charge was funded by the German Research Foundation (DFG) and the University of Freiburg in the funding programme Open Access Publishing.
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)